Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease
Movement Disorders Clinical Practice · 05.11.2026
DOI: 10.1002/mdc3.70885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 05.11.2026. Verfasst von Juliana Oliveira Freitas Silveira und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitário de Santa Maria, HUSM, Santa Maria, Brazil. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background
Neuroinflammation is implicated in Parkinson's disease (PD), and antidepressants may have anti‐inflammatory and motor benefits. The effects of duloxetine on inflammatory biomarkers and clinical outcomes in PD remain unclear.
Objectives
To assess changes in motor symptoms, quality of life, and serum cytokines during add‐on duloxetine treatment in PD.
Methods
Seventeen patients with PD without other chronic inflammatory diseases received add‐on duloxetine for 8 weeks in an open‐label, uncontrolled trial. Clinical outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr (HY), and Parkinson's Disease Questionnaire‐39 (PDQ‐39) scores. Serum TNF‐α, IL‐1β, IL‐6, and IL‐10 levels were measured at baseline and follow‐up.
Results
UPDRS, activities of daily living, and PDQ‐39 scores decreased during treatment. Ten patients achieved ≥5‐point UPDRS reductions. TNF‐α, IL‐1β, and IL‐6 decreased, whereas IL‐10 increased after treatment.
Conclusions
Add‐on duloxetine was associated with changes in clinical outcomes and inflammatory markers in patients with PD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Hospital Universitário de Santa Maria, HUSM, Santa Maria, Brazil.
- Pharmacology Graduate Program, Universidade Federal de Santa Maria UFSM, Santa Maria, Brazil.
- Neurology Department, Cooper University Hospital, Camden, New Jersey, USA.
- Biochemical Toxicology Graduate Program, Universidade Federal de Santa Maria, UFSM, Santa Maria, Brazil.
ORCID-Profile: Juliana Oliveira Freitas Silveira, Jamir Pitton Rissardo, Ana Letícia Fornari Caprara, Amanda Fernandes Klajn, Fernanda Rossatto Temp, Bruna Amanda Girardi, Paulo Gilberto Medeiros Jauris, Carlos Fernando Mello
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Silveira, J. O. F., Rissardo, J. P., Caprara, A. L. F., Klajn, A. F., Temp, F. R., Girardi, B. A., Duarte, M. M. M. F., Duarte, T., Jauris, P. G. M., & Mello, C. F. (2026). Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease. Movement Disorders Clinical Practice. https://doi.org/10.1002/mdc3.70885
Vancouver
Silveira JOF, Rissardo JP, Caprara ALF, Klajn AF, Temp FR, Girardi BA, et al. Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease. Movement Disorders Clinical Practice. 2026. doi:10.1002/mdc3.70885
BibTeX
@article{Silveira2026,
author = {Silveira, Juliana Oliveira Freitas and Rissardo, Jamir Pitton and Caprara, Ana Letícia Fornari and Klajn, Amanda Fernandes and Temp, Fernanda Rossatto and Girardi, Bruna Amanda and Duarte, Marta Maria Medeiros Frescura and Duarte, Thiago and Jauris, Paulo Gilberto Medeiros and Mello, Carlos Fernando},
title = {Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease},
journal = {Movement Disorders Clinical Practice},
year = {2026},
doi = {10.1002/mdc3.70885}
}
EUVIMED